NASDAQ · PCVX
Healthcare · Biotechnology
$60.62
Down-$1.41 (-2.27%)
Updated Nov 3, 2026, 6:08 AM
SID Score
6.3/10
Composite research score
Smart Money
55/100
Neutral
Price performance · PCVX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
PCVX closed at $60.62 after 21 trading sessions, down 17.88% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $61.88 | $62.87 | $60.15 | $60.62 | 1.32M |
| Oct 30, 2026 | $62.59 | $63.275 | $61.0204 | $62.03 | 1.71M |
| Oct 29, 2026 | $61.88 | $63.14 | $61.64 | $62.61 | 2.01M |
| Oct 28, 2026 | $59.92 | $63.94 | $59.58 | $61.46 | 2.21M |
| Oct 27, 2026 | $59.92 | $61.30 | $59.43 | $60.67 | 2.59M |
| Oct 26, 2026 | $60.68 | $61.50 | $59.19 | $59.97 | 1.47M |
| Oct 23, 2026 | $62.35 | $62.77 | $60.27 | $60.43 | 2.06M |
| Oct 22, 2026 | $62.96 | $64.58 | $61.56 | $62.85 | 2.77M |
| Oct 21, 2026 | $66.02 | $67.465 | $63.09 | $63.23 | 3.27M |
| Oct 20, 2026 | $63.80 | $67.01 | $63.68 | $66.23 | 1.96M |
| Oct 19, 2026 | $64.14 | $66.0188 | $63.375 | $63.68 | 2.55M |
| Oct 16, 2026 | $65.13 | $65.34 | $62.54 | $63.62 | 3.25M |
| Oct 15, 2026 | $67.72 | $68.33 | $65.00 | $65.27 | 2.45M |
| Oct 14, 2026 | $67.07 | $69.205 | $66.00 | $67.55 | 1.53M |
| Oct 13, 2026 | $70.58 | $71.09 | $66.63 | $66.80 | 2.81M |
| Oct 12, 2026 | $71.08 | $72.89 | $68.97 | $70.65 | 2.43M |
| Oct 9, 2026 | $64.78 | $72.44 | $64.78 | $71.38 | 4.38M |
| Oct 8, 2026 | $67.14 | $67.97 | $63.79 | $65.015 | 3.85M |
| Oct 7, 2026 | $65.86 | $67.15 | $64.27 | $66.96 | 11.56M |
| Oct 6, 2026 | $73.35 | $73.395 | $63.8997 | $66.70 | 10.16M |
| Oct 5, 2026 | $87.21 | $90.75 | $71.60 | $73.82 | 14.92M |
The latest Smart Investors Daily articles mentioning PCVX.
Company
Market Activity
Research & News
PCVX research
Company profile and research snapshot.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 12, 2026 | Cantor Fitzgerald | Overweight | — |
| Oct 5, 2026 | Needham | Buy | — |
| Oct 5, 2026 | BTIG | Buy | — |
| Oct 5, 2026 | Guggenheim | Buy | — |
| Sep 28, 2026 | B of A Securities | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 30, 2026
The mean of analysts' price targets for Vaxcyte (PCVX) points to an 87.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SeekingAlpha · Oct 19, 2026
Vaxcyte is a late clinical-stage vaccine company positioned as a potential disruptor in the vaccine market. Learn more about PCVX stock here.
Yahoo · Oct 14, 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 75.6% in Vaxcyte (PCVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Benzinga · Oct 12, 2026
Cantor Fitzgerald analyst Carter Gould reiterates Vaxcyte (NASDAQ:PCVX) with a Overweight and announces $120 price target.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PCVX.
